1. Home
  2. IGC

IGC

IGC Pharma Inc.

Logo IGC Pharma Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-18-2024 3:31pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
-
.
-
-
%

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Founded: 2005 Country:
United States
United States
Employees: N/A City: POTOMAC
Market Cap: 29.1M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 884.1K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.26 EPS Growth: N/A
52 Week Low/High: $0.25 - $0.91 Next Earning Date: 02-14-2024
Revenue: $1,216,000 Revenue Growth: 40.09%
Revenue Growth (this year): 37.76% Revenue Growth (next year): 12.59%

Share on Social Networks: